Bellerophon Therapeutics, Inc. (BLPH)
- Previous Close
0.0586 - Open
0.0522 - Bid --
- Ask --
- Day's Range
0.0522 - 0.0612 - 52 Week Range
0.0290 - 11.1500 - Volume
47,040 - Avg. Volume
45,871 - Market Cap (intraday)
661,783 - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8900 - Earnings Date Apr 24, 2024 - Apr 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
bellerophon.comRecent News: BLPH
Performance Overview: BLPH
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLPH
Valuation Measures
Market Cap
716.83k
Enterprise Value
-14.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.12
Price/Book (mrq)
0.19
Enterprise Value/Revenue
-2.56
Enterprise Value/EBITDA
1.31
Financial Highlights
Profitability and Income Statement
Profit Margin
-164.06%
Return on Assets (ttm)
-78.47%
Return on Equity (ttm)
-165.96%
Revenue (ttm)
5.64M
Net Income Avi to Common (ttm)
-9.25M
Diluted EPS (ttm)
-0.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.7M